DAPAGLIFLOZIN AND METOPROLOL BOTH COMBINATION DRUGS USED IN TREATMENT OF HEART FAILURE
Nidhi Tadvi*, Krishna Kalsara and Dr. Umesh Upadhyay
ABSTRACT
Based on the results from dedicated cardiovascular outcome trials (CVOTs), current guidelines suggest the use of SGLT-2 inhibitors for patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) or heart failure.
Keywords: Heart failure, dapagliflozin, metoprolol.
[Download Article]
[Download Certifiate]